Cabozantinib significantly prolongs PFS compared to sunitinib in papillary RCC
The results from SWOG 1500 were presented at ASCO GU 2021 and show that cabozantinib provides a statistically significant and clinically meaningful prolongation of progression-free survival compared to sunitinib in patients with metastatic papillary renal cell carcinoma.